Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Technology Strategy Board Appoints Cell Therapy Catapult CEO

Published: Monday, April 30, 2012
Last Updated: Monday, April 30, 2012
Bookmark and Share
Mr Keith Thompson will be responsible for short and long-term objectives of the Catapult.

The Technology Strategy Board has appointed life science innovator Keith Thompson as Chief Executive Officer of the Catapult centre in cell therapy.

Mr Thompson brings strong leadership and considerable senior executive and management experience in the biotechnology industry both in the UK and abroad.

Mr Thompson, who will start on 1 May, will be responsible for short and long-term objectives of the Catapult, including where the centre will be based and recruiting an executive team.

He will also be in charge of developing and delivering against a robust business plan and key milestones that will help grow the industry.

When operational, the cell therapy Catapult will work to grow a viable and sustainable UK-based cell therapy industry with access to finance, clinical and technical expertise to allow the rapid exploitation of cell therapies.

The Catapult will enable the UK to be a global leader in the development and commercial exploitation of cell therapies and encourage inward investment to support the growth of the commercial sector.

It will also work with UK companies to help turn innovations in cell therapies into commercial products capable of transforming the lives of people with serious or chronic illnesses.

Mr Thompson joins the Catapult from the Scottish National Blood Transfusion Service (SNBTS). As Director of the SNBTS he was responsible for all aspects of the service including the safe and sufficient supply of blood and tissues, as well as diversifying its capability to offer cell-based therapies.

Prior to this, Thompson held various senior domestic and international positions at Serologicals where he designed, built and licensed major biotechnology manufacturing facilities in the UK, US and Canada, to produce monoclonal antibodies and mammalian cell culture supplements.

Iain Gray, Chief Executive of the Technology Strategy Board said: “We are delighted that Keith has joined us at this important stage of establishing the Catapult. He has shown strong leadership qualities throughout his career and brings considerable life science and international business experience to the Catapult. His US experience with Serologicals sends a powerful message regarding our ambition to quickly establish an international reputation for the Cell Therapy Catapult.”

Keith Thompson said: “The Cell Therapy Catapult is an exciting initiative, which promises to offer the next major advances in healthcare using cells to repair, regenerate and replace damaged tissues. The UK has led the science of cell therapy and the Catapult aims to help translate this into real benefits for patients and business.”

The Catapult is part of a network of world-leading technology and innovation centers established and overseen by the Technology Strategy Board as a long-term investment that will open up global opportunities for the UK and generate economic growth for the future.

The cell therapy Catapult will be based in London and aims to open for business in the autumn.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UK to Invest up to £2.8M in Bioscience Research
The investment in collaborative feasibility studies aims to stimulate innovation across four technology areas that will enable and underpin UK growth.
Thursday, April 17, 2014
New Research will Help make Foods Healthier, Safer and More Nutritious
Over fifty research projects and studies aimed at developing healthier, safer and more nutritious food are to share over £7 million of UK government investment.
Tuesday, October 11, 2011
Funding Agreed for Four Collaborative Research and Development Projects in Industrial Biotechnology
Four projects that will develop and commercialize innovative processes to generate high value chemicals to share £1.5 million of support funding.
Monday, April 18, 2011
New Funding Scheme will Support Innovative Small Companies
Enable companies to research and develop new products, processes and services that could stimulate economic growth.
Tuesday, March 22, 2011
Small Companies to Share £2.5M in new Government Investment to Develop Industrial Biotechnology Processes
The government has announced that it is to invest £2.5 million to stimulate innovation in the UK’s industrial biotechnology sector, with most funding going to small and medium-sized companies.
Friday, March 12, 2010
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!